iShares US Pharmaceuticals ETF
IHE
IHE
139 hedge funds and large institutions have $326M invested in iShares US Pharmaceuticals ETF in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
139
Holders Change
-10
Holders Change %
-6.71%
% of All Funds
1.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
41
Reduced
39
Closed
24
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$13.1M |
| 2 |
JPMorgan Chase & Co
New York
|
+$6.45M |
| 3 |
Goldman Sachs
New York
|
+$2.21M |
| 4 |
GC
Grimes & Company
Westborough,
Massachusetts
|
+$1.47M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.29M |
Top Sellers
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$10.9M |
| 2 |
ClearBridge Investments
New York
|
-$1.9M |
| 3 |
Morgan Stanley
New York
|
-$1.89M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.35M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.26M |
